Psyched: Ibogaine For TBI, Kentucky Initiative Halts, DEA Stakes, Insurance Tokens, $50M For Atai And More – ATAI Life Sciences (NASDAQ:ATAI), Clearmind Medicine (NASDAQ:CMND)

Ibogaine treatment shows promising results for veterans with traumatic brain injuries

Results A First-ever clinical trial of ibogaine and magnesium therapy for Special Operations Veterans (SOV) With repeated exposure to the explosion it was published in the magazine nature. Although preliminary, the results have been long awaited as they appear Evidence for the neurorestorative effects of ibogaine.

Led by the Director of the Brain Stimulation Laboratory at Stanford University Dr. Nolan WilliamsThis study is the first prospective, physician-rated trial of ibogaine compared to previous published studies of ibogaine, with results based on self-reports. Continue reading here.

Kentucky’s promising initiative to treat opioid addiction falters as new attorney general ousts lead attorney

Once A promising leading country in ibogaine research To treat Opioid use disorderKentucky’s appointment of Attorney General Russell Coleman brought the problem to light Remove Brian Hubbard.

As President and CEO of Kentucky Opioid Abatement Advisory Committee (KYOAAC)Hubbard led the proposal to use 5% (or $42 million) of the state’s $900 million opioid settlements to fund ibogaine studies. Continue reading here.

DEA raises production quotas for THC, Psilocybin, and DMT for scientific research purposes

the DEA proposes production Higher amounts of THC, psilocybin and DMR for research in 2024. In a notice scheduled to be published in the Federal Register on Wednesday, the agency said it was raising the proposed amounts in response to a request from registered producers, Marijuana Moment wrote.

This shows a Continuing trendThe Drug Enforcement Administration had previously increased the manufacturing quotas for these substances in the years 2021, 2022, and 2023. Continue reading here.

AMA Reimbursement Codes for Psychedelic-Assisted Therapies Take Effect: Here’s What to Expect

the New American Medical Association Coverage and Reimbursement Codes For drug-assisted therapies approved by the US Food and Drug Administration, Current Procedural Terminology (CPT) III codes are now active for use by physicians and other qualified health care providers.

These are temporary codes designated for emerging technologies, services, and procedures, to facilitate reimbursement and support access to psychedelic therapies in the United States Continue reading here.

Atai is investing $50 million in Beckley Psytech to develop short-acting psychedelics

Biopharmaceutical and resource pooling company Atay Life Sciences (NASDAQ:ATAI) invested a total of $50 million in Beckley Psytech Ltd. A British clinical-stage biotechnology company developing short-acting anesthetic drugs to treat neuropsychiatric conditions.

After investment – $40 million direct and an additional $10 million in secondary stock purchases from existing shareholders. Beckley Psytech will remain an independent, private company, with Atai owning 35.5%. Details here.

Teacher tour

SEE ALSO: Last week’s edition of “Psyched”

Weekly performance of Psychedelics ETF

Dope ETF Stock Advisor (NYSE: BSL) opened Tuesday, January 2 Priced at $1.42following previous opens of $1.42, $1.34, and $1.31 (December 26, 18, and 11, respectively).

On Friday, January 5 that It closed at $1.44following previous closes of $1.39, $1.42, and $1.38 (December 29, 22, and 15, respectively).

Highest level of the week It was $1.62 on Wednesday, January 3, versus the previous weeks highs of $1.45, $1.43, and $1.41.

The low for the week was $1.35 on Thursday, January 4, versus the previous weeks’ lows of $1.32, $1.32, and $1.29.

Psychedelic shares traded highest on Friday, January 5 at the close

• Compass paths (NASDAQ:CMPS) closed at $8.76, approx. evening The immediate previous close was at $8.75 ($8.75) and before the last three weeks’ close of $7.95.

• GH Research (NASDAQ:GHRS) closed at $5.37, a little late The previous weeks closed at $5.80, $5.49, and $5.71.

• Mind Medicine (MindMed) (NASDAQ:MNMD) closed at $4.13, jump From previous closes of $3.69, $3.57, and $3.40.

• Enkanix Healthcare (NASDAQ:IXHL) closed at $4.10, back Just before closing at $4.64, yet still ahead of the last two and three weeks’ prices of $3.92 and $3.84.

• Clear Mind Medicine (NASDAQ:CMND) closed at $2.28, down From previous closes of $2.85, $2.95 and $2.77.

• Bright Minds Biosciences (NASDAQ:DRUG) closed at $1.68, absorption As of previous closes of $1.43, $1.50, and $1.49.

• Atay Life Sciences (NASDAQ:ATAI) closed at $1.64, absorption As of previous closes at $1.41, $1.40, and $1.27.

• Pharma silo (NASDAQ:SILO) closed at $1.46, which is a mixed trend Compared to previous closes of $1.44, $1.60, and $1.47.

• Selous Treatments (NASDAQ:SEEL) closed at $1.34, down From all previous closes at $1.43, $1.56 and $1.59.

• Inveric Biosciences (NASDAQ:ENVB) closed at $1.27, similar to previous closes of $1.30, $1.32, and $1.36.

The above stock trading numbers are according to Benzinga Pro, the streaming platform that has all the information you need that helps you invest smarter – join us and see for yourself!